Tri Chemical Laboratories (4369) Q2 2025 earnings summary

Executive summary

• Net sales for the six months ended July 31, 2024, rose 41.8% year-over-year to ¥7,974 million, with operating profit up 76.2% to ¥1,939 million and profit attributable to owners of parent up 39.8% to ¥2,031 million.

• Comprehensive income increased 39.1% year-over-year to ¥2,177 million for the period.

Financial highlights

• Gross profit for the six months was ¥3,203 million, up from ¥2,156 million year-over-year.

• Ordinary profit increased 40.6% year-over-year to ¥2,680 million.

• Basic earnings per share rose to ¥62.51 from ¥44.72 in the prior year period.

• Total assets as of July 31, 2024, were ¥33,529 million, up from ¥31,864 million as of January 31, 2024.

• Net assets increased to ¥28,772 million, with an equity ratio of 85.8%.

Outlook and guidance

• Full-year net sales forecast is ¥17,000 million, up 51.2% year-over-year, with operating profit expected to double to ¥3,900 million.

• Profit attributable to owners of parent is forecast at ¥4,260 million, up 72.4% year-over-year, and basic EPS at ¥131.09.

• Dividend forecast for the year is ¥30 per share at both the 2nd quarter-end and year-end.